CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer
Abstract Objective Changes in CA 125 with chemotherapy predict outcome for epithelial ovarian cancer. There is no such data for advanced endometrial cancer. Method Retrospective review of all women receiving carboplatin and paclitaxel for advanced endometrial cancer at any of the institutions of the...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 2011-01, Vol.120 (1), p.52-55 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 52 |
| container_title | Gynecologic oncology |
| container_volume | 120 |
| creator | Hoskins, P.J Le, N Correa, R |
| description | Abstract Objective Changes in CA 125 with chemotherapy predict outcome for epithelial ovarian cancer. There is no such data for advanced endometrial cancer. Method Retrospective review of all women receiving carboplatin and paclitaxel for advanced endometrial cancer at any of the institutions of the British Columbia Cancer Agency between September 1995 and September 2006. Results 185 newly diagnosed women were treated. Univariable analysis for progression-free survival identified as adverse predictors: grade 3, positive residual, age > 60, deep myometrial invasion, increasing stage/substage, papillary serous subtype, presence of cervical involvement, ECOG 1 or greater, CA 125 above 35 either preoperatively or at start of cycle 1 and CA 125 greater than 24 at the start of cycle 3. Upon multivariate analysis, CA 125 above 24 at cycle 3, grade 3 and positive residual remained as independent predictors. The single most important factor identified by decision tree analysis was CA 125 level at cycle 3. Conclusion As with epithelial ovarian cancer, changes in CA 125 are highly predictive of outcome for advanced, chemotherapy treated endometrial cancer. |
| doi_str_mv | 10.1016/j.ygyno.2010.09.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_816387188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825810006943</els_id><sourcerecordid>816387188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-82b3bff69c73ab4d4c007ce2638fd7cafa556d6076bbdec9aae3c859f54efa5c3</originalsourceid><addsrcrecordid>eNqFkU2PFCEQhonRuOPqLzAx3DzNWDT9xUGTzcSvZBMP6pnQUO0wdkMLdG_aXy_trB68eIHk5a23qKcIec7gwIDVr86H9dvq_KGArIA4ACsfkB0DUe3rthIPyQ5AwL4tqvaKPInxDAAcWPGYXBUgyoZVxY6MxxvKioo6H0Y12J8qWe_onU0nqk84-nTCoKaV2kitMzhhPlwaVjoFNFYnuyD1PY1zWOyihmyiyizKaTQ0e_2IKdis600KT8mjXg0Rn93f1-Tru7dfjh_2t5_efzze3O51yXjKX-541_e10A1XXWlKDdBoLGre9qbRqldVVZsamrrrDGqhFHKdR-6rEvOb5tfk5SV3Cv7HjDHJ0UaNw6Ac-jnKluWohrVtdvKLUwcfY8BeTsGOKqySgdwwy7P8jVlumCUImTHnqhf3-XM3ovlb84drNry-GDBPuVgMMmqLGxUbUCdpvP1Pgzf_1OvBOqvV8B1XjGc_B5cBSiZjIUF-3ja9LZrlHdei5PwX_5unUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>816387188</pqid></control><display><type>article</type><title>CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hoskins, P.J ; Le, N ; Correa, R</creator><creatorcontrib>Hoskins, P.J ; Le, N ; Correa, R</creatorcontrib><description>Abstract Objective Changes in CA 125 with chemotherapy predict outcome for epithelial ovarian cancer. There is no such data for advanced endometrial cancer. Method Retrospective review of all women receiving carboplatin and paclitaxel for advanced endometrial cancer at any of the institutions of the British Columbia Cancer Agency between September 1995 and September 2006. Results 185 newly diagnosed women were treated. Univariable analysis for progression-free survival identified as adverse predictors: grade 3, positive residual, age > 60, deep myometrial invasion, increasing stage/substage, papillary serous subtype, presence of cervical involvement, ECOG 1 or greater, CA 125 above 35 either preoperatively or at start of cycle 1 and CA 125 greater than 24 at the start of cycle 3. Upon multivariate analysis, CA 125 above 24 at cycle 3, grade 3 and positive residual remained as independent predictors. The single most important factor identified by decision tree analysis was CA 125 level at cycle 3. Conclusion As with epithelial ovarian cancer, changes in CA 125 are highly predictive of outcome for advanced, chemotherapy treated endometrial cancer.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2010.09.014</identifier><identifier>PMID: 20947152</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; CA 125 ; CA-125 Antigen - blood ; Carboplatin - administration & dosage ; Carcinoma, Endometrioid - blood ; Carcinoma, Endometrioid - drug therapy ; Chemotheraphy ; Disease-Free Survival ; Endometrial cancer ; Endometrial Neoplasms - blood ; Endometrial Neoplasms - drug therapy ; Endometrial Neoplasms - pathology ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Obstetrics and Gynecology ; Paclitaxel - administration & dosage ; Predictive Value of Tests ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Gynecologic oncology, 2011-01, Vol.120 (1), p.52-55</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>Copyright © 2010 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-82b3bff69c73ab4d4c007ce2638fd7cafa556d6076bbdec9aae3c859f54efa5c3</citedby><cites>FETCH-LOGICAL-c413t-82b3bff69c73ab4d4c007ce2638fd7cafa556d6076bbdec9aae3c859f54efa5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ygyno.2010.09.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20947152$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoskins, P.J</creatorcontrib><creatorcontrib>Le, N</creatorcontrib><creatorcontrib>Correa, R</creatorcontrib><title>CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Objective Changes in CA 125 with chemotherapy predict outcome for epithelial ovarian cancer. There is no such data for advanced endometrial cancer. Method Retrospective review of all women receiving carboplatin and paclitaxel for advanced endometrial cancer at any of the institutions of the British Columbia Cancer Agency between September 1995 and September 2006. Results 185 newly diagnosed women were treated. Univariable analysis for progression-free survival identified as adverse predictors: grade 3, positive residual, age > 60, deep myometrial invasion, increasing stage/substage, papillary serous subtype, presence of cervical involvement, ECOG 1 or greater, CA 125 above 35 either preoperatively or at start of cycle 1 and CA 125 greater than 24 at the start of cycle 3. Upon multivariate analysis, CA 125 above 24 at cycle 3, grade 3 and positive residual remained as independent predictors. The single most important factor identified by decision tree analysis was CA 125 level at cycle 3. Conclusion As with epithelial ovarian cancer, changes in CA 125 are highly predictive of outcome for advanced, chemotherapy treated endometrial cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>CA 125</subject><subject>CA-125 Antigen - blood</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Endometrioid - blood</subject><subject>Carcinoma, Endometrioid - drug therapy</subject><subject>Chemotheraphy</subject><subject>Disease-Free Survival</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - blood</subject><subject>Endometrial Neoplasms - drug therapy</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Obstetrics and Gynecology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Predictive Value of Tests</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2PFCEQhonRuOPqLzAx3DzNWDT9xUGTzcSvZBMP6pnQUO0wdkMLdG_aXy_trB68eIHk5a23qKcIec7gwIDVr86H9dvq_KGArIA4ACsfkB0DUe3rthIPyQ5AwL4tqvaKPInxDAAcWPGYXBUgyoZVxY6MxxvKioo6H0Y12J8qWe_onU0nqk84-nTCoKaV2kitMzhhPlwaVjoFNFYnuyD1PY1zWOyihmyiyizKaTQ0e_2IKdis600KT8mjXg0Rn93f1-Tru7dfjh_2t5_efzze3O51yXjKX-541_e10A1XXWlKDdBoLGre9qbRqldVVZsamrrrDGqhFHKdR-6rEvOb5tfk5SV3Cv7HjDHJ0UaNw6Ac-jnKluWohrVtdvKLUwcfY8BeTsGOKqySgdwwy7P8jVlumCUImTHnqhf3-XM3ovlb84drNry-GDBPuVgMMmqLGxUbUCdpvP1Pgzf_1OvBOqvV8B1XjGc_B5cBSiZjIUF-3ja9LZrlHdei5PwX_5unUw</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Hoskins, P.J</creator><creator>Le, N</creator><creator>Correa, R</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer</title><author>Hoskins, P.J ; Le, N ; Correa, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-82b3bff69c73ab4d4c007ce2638fd7cafa556d6076bbdec9aae3c859f54efa5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>CA 125</topic><topic>CA-125 Antigen - blood</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Endometrioid - blood</topic><topic>Carcinoma, Endometrioid - drug therapy</topic><topic>Chemotheraphy</topic><topic>Disease-Free Survival</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - blood</topic><topic>Endometrial Neoplasms - drug therapy</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Obstetrics and Gynecology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Predictive Value of Tests</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoskins, P.J</creatorcontrib><creatorcontrib>Le, N</creatorcontrib><creatorcontrib>Correa, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoskins, P.J</au><au>Le, N</au><au>Correa, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>120</volume><issue>1</issue><spage>52</spage><epage>55</epage><pages>52-55</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Objective Changes in CA 125 with chemotherapy predict outcome for epithelial ovarian cancer. There is no such data for advanced endometrial cancer. Method Retrospective review of all women receiving carboplatin and paclitaxel for advanced endometrial cancer at any of the institutions of the British Columbia Cancer Agency between September 1995 and September 2006. Results 185 newly diagnosed women were treated. Univariable analysis for progression-free survival identified as adverse predictors: grade 3, positive residual, age > 60, deep myometrial invasion, increasing stage/substage, papillary serous subtype, presence of cervical involvement, ECOG 1 or greater, CA 125 above 35 either preoperatively or at start of cycle 1 and CA 125 greater than 24 at the start of cycle 3. Upon multivariate analysis, CA 125 above 24 at cycle 3, grade 3 and positive residual remained as independent predictors. The single most important factor identified by decision tree analysis was CA 125 level at cycle 3. Conclusion As with epithelial ovarian cancer, changes in CA 125 are highly predictive of outcome for advanced, chemotherapy treated endometrial cancer.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20947152</pmid><doi>10.1016/j.ygyno.2010.09.014</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2011-01, Vol.120 (1), p.52-55 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_816387188 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use CA 125 CA-125 Antigen - blood Carboplatin - administration & dosage Carcinoma, Endometrioid - blood Carcinoma, Endometrioid - drug therapy Chemotheraphy Disease-Free Survival Endometrial cancer Endometrial Neoplasms - blood Endometrial Neoplasms - drug therapy Endometrial Neoplasms - pathology Female Hematology, Oncology and Palliative Medicine Humans Middle Aged Multivariate Analysis Neoplasm Staging Obstetrics and Gynecology Paclitaxel - administration & dosage Predictive Value of Tests Retrospective Studies Treatment Outcome |
| title | CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T07%3A26%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CA%20125%20normalization%20with%20chemotherapy%20is%20independently%20predictive%20of%20survival%20in%20advanced%20endometrial%20cancer&rft.jtitle=Gynecologic%20oncology&rft.au=Hoskins,%20P.J&rft.date=2011-01-01&rft.volume=120&rft.issue=1&rft.spage=52&rft.epage=55&rft.pages=52-55&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2010.09.014&rft_dat=%3Cproquest_cross%3E816387188%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=816387188&rft_id=info:pmid/20947152&rft_els_id=S0090825810006943&rfr_iscdi=true |